Docosahexaenoic acid therapy in peroxisomal diseases Results of a double-blind, randomized trial

University of Texas Medical Branch, Galveston, TX, USA.
Neurology (Impact Factor: 8.29). 08/2010; 75(9):826-30. DOI: 10.1212/WNL.0b013e3181f07061
Source: PubMed


Peroxisome assembly disorders are genetic disorders characterized by biochemical abnormalities, including low docosahexaenoic acid (DHA). The objective was to assess whether treatment with DHA supplementation would improve biochemical abnormalities, visual function, and growth in affected individuals.
This was a randomized, double-blind, placebo-controlled trial conducted at a single center. Treatment groups received supplements of DHA (100 mg/kg per day). The primary outcome measures were the change from baseline in the visual function and physical growth during the 1 year follow-up period.
Fifty individuals were enrolled and randomized. Two were subsequently excluded from study analysis when it was determined that they had a single enzyme disorder of peroxisomal beta oxidation. Thirty-four returned for follow-up. Nine patients died during the trial of their disorder, and 5 others were lost to follow-up. DHA supplementation was well tolerated. There was no difference in the outcomes between the treated and untreated groups in biochemical function, electroretinogram, or growth. Improvements were seen in both groups in certain individuals.
DHA supplementation did not improve the visual function or growth of treated individuals with peroxisome assembly disorders. Classification of evidence: This interventional study provides Class II evidence that DHA supplementation did not improve the visual function or growth of treated individuals with peroxisome assembly disorders during an average of 1 year of follow-up in patients aged 1 to 144 months.

Download full-text


Available from: Linah Albanna, Aug 18, 2014
  • Source
    • "Currently, there is no cure for ZSDs and possibilities for supportive and symptomatic treatment are limited. Some patients received docosahexaenoic acid without any proven positive effect [25]. In addition, some patients follow a phytanic acid reduced diet and are supplemented with fat-soluble vitamins [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Zellweger spectrum disorders (ZSDs) are multisystem genetic disorders caused by a lack of functional peroxisomes, due to mutations in one of the PEX genes, encoding proteins involved in peroxisome biogenesis. The phenotypic spectrum of ZSDs ranges from an early lethal form to much milder presentations. In cultured skin fibroblasts from mildly affected patients, peroxisome biogenesis can be partially impaired which results in a mosaic catalase immunofluorescence pattern. This peroxisomal mosaicism has been described for specific missense mutations in various PEX genes. In cell lines displaying peroxisomal mosaicism, peroxisome biogenesis can be improved when these are cultured at 30[degree sign]C. This suggests that these missense mutations affect the folding and/or stability of the encoded protein. We have studied if the function of mutant PEX1, PEX6 and PEX12 can be improved by promoting protein folding using the chemical chaperone arginine. Fibroblasts from three PEX1 patients, one PEX6 and one PEX12 patient were cultured in the presence of different concentrations of arginine. To determine the effect on peroxisome biogenesis we studied the following parameters: number of peroxisome-positive cells, levels of PEX1 protein and processed thiolase, and the capacity to beta-oxidize very long chain fatty acids and pristanic acid. Peroxisome biogenesis and function in fibroblasts with mild missense mutations in PEX1, 6 and 12 can be improved by arginine. Arginine may be an interesting compound to promote peroxisome function in patients with a mild peroxisome biogenesis disorder.
    Orphanet Journal of Rare Diseases 09/2013; 8(1):138. DOI:10.1186/1750-1172-8-138 · 3.36 Impact Factor
  • Source
    • "Increases of the DHA pool and improves visual functions. Paker et al. 2010 (44) Double-blind, placebo- controlled randomized trial 50 children with peroxisomal disorders (1 months-10y) "
    [Show abstract] [Hide abstract]
    ABSTRACT: A number of studies are investigating the role of n-3 polyunsaturated fatty acids in children with metabolic inborn errors, while the effects on visual and brain development in premature infants and neonates are well known. However, their function incertain chronic neurological, inflammatory and metabolic disorders is still under study. Standards should be established to help identify the need of docosahexaenoic acid supplementation in conditions requiring a restricted diet resulting in an altered metabolism system, and find scientific evidence on the effects of such supplementation. This study reviews relevant published literature to propose adequate n-3 intake or supplementation doses for different ages and pathologies. The aim of this review is to examine the effects of long chain polyunsaturated fatty acids supplementation in preventing cognitive impairment or in retarding its progress, and to identify nutritional deficiencies, in children with inborn errors of metabolism. Trials were identified from a search of the Cochrane and MEDLINE databases in 2011. These databases include all major completed and ongoing double-blind, placebo-controlled, randomized trials, as well as all studies in which omega-3 supplementation was administered to children with inborn errors, and studies assessing omega-3 fatty acids status in plasma in these pathologies. Although few randomized controlled trials met the inclusion criteria of this review, some evidenced that most of children with inborn errors are deficient in omega-3 fatty acids, and demonstrated that supplementation might improve their neural function, or prevent the progression of neurological impairment. Nontheless, further investigations are needed on this issue.
    The British journal of nutrition 06/2012; 107 Suppl 2(S2):S129-36. DOI:10.1017/S0007114512001523 · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: To evaluate, for individuals with chronic stroke with cognitive impairment, 1) the effects of a practice test on peak cardiorespiratory fitness test results, 2) cardiorespiratory fitness test-retest reliability, and 3) the relationship between individual practice test effects and cognitive impairment. DESIGN: Cross-sectional SETTING: Rehabilitation center PARTICIPANTS: A convenience sample of 21 persons (12 men and 9 women, 48-81 years old, 44.9±36.2 months post stroke) with cognitive impairments who had sufficient lower limb function to perform the test. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: Peak oxygen consumption (VO2peak, ml kgˆ(-1)∙minˆ(-1)) RESULTS: Test-retest reliability of VO2peak, was excellent (ICC2,1=.94, CI95%=.86-.98). A paired t-test showed that there was no significant difference for the group for VO2peak obtained from two symptom limited cardiorespiratory fitness tests, performed one week a part, on a semi-recumbent cycle ergometer (test 2-test 1 difference= -.32 ml∙kgˆ(-1)∙minˆ(-1), 95% confidence interval CI95%=-.69-1.33 ml ∙kgˆ(-1)∙minˆ(-1), P=.512). Individual test-retest differences in VO2peak, were, however, positively related to general cognitive function as measured by the Mini-Mental State Examination (rho=.485; P<.026). CONCLUSION: VO2peak can be reliably measured in this group without a practice test. General cognitive function, however, may influence the effect of a practice test in that those with lower general cognitive function appear to respond differently to a practice test than those with higher cognitive function.
    Archives of physical medicine and rehabilitation 04/2013; 94(11). DOI:10.1016/j.apmr.2013.03.016 · 2.57 Impact Factor
Show more